Generali Asset Management’s Royalty Pharma RPRX Stock Holding History

Generali Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.9K	Buy	1,425 +996	+232%	+$51.8K	﹤0.01%	475
2026 Q1	$20.6K	Sell	429 -5	-1%	-$219	﹤0.01%	466
2025 Q4	$16.8K	Sell	434 -33,647	-99%	-$1.28M	﹤0.01%	468
2025 Q3	$1.2M	Buy	34,081 +33,647	+7,753%	+$1.22M	0.03%	388
2025 Q2	$15.6K	Sell	434 -94,251	-100%	-$3.12M	﹤0.01%	488
2025 Q1	$2.95M	Buy	94,685 +94,232	+20,802%	+$2.99M	0.07%	239
2024 Q4	$11.6K	Buy	+453	New	+$12K	﹤0.01%	470

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Generali Asset Management's RPRX Position: Q2 2026 in Review

Generali Asset Management increased its Royalty Pharma (RPRX) stake by 232% in Q2 2026, buying an estimated $51.8K and bringing the position to 1,425 shares worth $79.9K. The position accounts for ﹤0.01% of the portfolio, ranked #475.

Generali Asset Management first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.95M in Q1 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Generali Asset Management held 1,425 shares of Royalty Pharma worth $79.9K as of Q2 2026.
Generali Asset Management bought 996 Royalty Pharma shares in Q2 2026, an estimated $51.8K.
Royalty Pharma made up ﹤0.01% of Generali Asset Management's portfolio in Q2 2026, its #475 holding.
Generali Asset Management first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
Generali Asset Management's Royalty Pharma position peaked at $2.95M in Q1 2025.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Generali Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.